GSK (GSK) and Japan's Shionogi said Wednesday that the latter has completed its acquisition of 11.7% stake in ViiV Healthcare from Pfizer (PFE) for about $2.13 billion.

Under the terms, Pfizer received $1.88 billion while GSK received a special dividend of $250 million, payable in British pounds, the companies said.

With the acquisition, Shionogi now owns a 21.7% economic stake in ViiV, while GSK retains its 78.3% majority stake, according to the parties.

The deal was first announced on Jan. 20.